Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine

Ítems similars

• Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
  per: Fiorelli, Alfonso, et al.
  Publicat: (2020)
• Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?
  per: Arulananda, Surein, et al.
  Publicat: (2020)
• EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials
  per: Wu, Jing-Xun, et al.
  Publicat: (2018)
• Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era?
  per: Mountzios, Giannis
  Publicat: (2018)
• Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer
  per: Tanaka, Satomi, et al.
  Publicat: (2019)